

Statement

To whom it may concern

We, Wuhan UNscience Biotechnology Co., Ltd, hereby, declare below information.

A SARS-CoV-2 variant, referred to new coronavirus mutant B1.1.7 (SARS-CoV-2 VOC 202012/01), has been identified through viral genomic sequencing in the United Kingdom (UK). It is defined by multiple spike protein mutations (deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H) present; new coronavirus mutant B.1.351 identified in S. Africa, which has a mutation in the RBD of the Spike protein (N501Y); new coronavirus mutant P.1 identified in Brazil which has mutations include E484K, K417T, and N501Y in spike gene; new coronavirus mutant B.1.617 identified in India which has mutations include E484Q, L452R, E154K and P681R in spike gene; C.37 identified in Peru presents seven mutations in the spike gene Δ 247-253, G75V, T76I, L452Q, F490S, T859N.

Our CP04009/ SARS-COV-2 Antigen Rapid Test Kit is designated to detect nucleocapsid protein (NP) of SARS-CoV-2 virus. Thus, above mentioned spike protein mutation SARS-CoV-2 variant found in U.K., S. Africa, Brazil India and Peru are not affecting virus performance of CP04009/ SARS-COV-2 Antigen Rapid Test Kit. We declare that CP04009/ SARS-COV-2 Antigen Rapid Test Kit can detect SARS-CoV-2 variant in U.K., S. Africa, Brazil, India and Peru with same performance of other currently known strains of SARS-CoV-2 virus.

